Meeting
2017 ASCO Annual Meeting
A phase I study to assess the safety, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activities of daily oral BAL101553, a novel tumor checkpoint controller (TCC) in adult patients with progressive or recurrent glioblastoma (GBM) or high-grade glioma.
Authors
Alvaro Henrique Ingles Garces
The Royal Marsden Hospital and The Institute of Cancer Research, London, United Kingdom
Alvaro Henrique Ingles Garces , Elizabeth R. Plummer , Juanita Suzanne Lopez , Rebecca Sophie Kristeleit , Julie MacDonald , Lorna Sweeting , Michael-John Devlin , Yvette Drew , Alison L. Hannah , Nicola Aceto , Stephanie Anderson , Heidi A Lane , Patrice Larger , Martina Maurer , Phil McKernan , Marc Frederick Engelhardt , Alastair Greystoke , Niamh Coleman , T.R. Jeffry Evans , Paul James Mulholland
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics
Track
Developmental Therapeutics and Translational Research
Sub Track
Chemotherapy
Clinical Trial Registration Number
NCT02490800
Citation
J Clin Oncol 35, 2017 (suppl; abstr TPS2601)
DOI
10.1200/JCO.2017.35.15_suppl.TPS2601
Abstract #
TPS2601
Poster Bd #
90b
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
A phase I study to assess the safety, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activities of BAL101553, a novel tumor checkpoint controller (TCC), administered as 48-hour infusion in adult patients with advanced solid tumors.
First Author: Markus Joerger
Poster
2022 ASCO Annual Meeting
DSP-0390, an oral emopamil binding protein (EBP) inhibitor, in patients with recurrent high-grade glioma: A first-in-human, phase 1 study.
First Author: David A. Reardon
Poster
2023 ASCO Annual Meeting
A phase 0 pharmacokinetic trigger trial of infigratinib in patients with recurrent high-grade glioma.
First Author: Nader Sanai
Poster
2023 ASCO Annual Meeting
An exploratory clinical trial on intra-lumbar injection of B7H3-specific allogeneic universal CAR-T cells in patients with recurrent high-grade gliomas.
First Author: Xiaoyun Shang